Adult acute leukemia most commonly manifests as acute myeloid leukemia (AML), a highly heterogeneous malignant tumor of the blood system. The application of genetic diagnostic technology is currently prevalent in numerous clinical sectors. According to recent research, the presence of specific gene mutations or rearrangements in leukemia cells is the primary cause of the disease. As different types of leukemia are caused by atypical mutated genes, testing for these mutations or rearrangements can help diagnose leukemia and identify the disease’s molecular targets for treatment.
Methods:
Using the search fields “WT1,” “DNMT3A,” “Acute myeloid leukemia,” and “survival,” the CBM, Cochrane Library, Scopus, EMBASE, and PUBMED databases were separately reviewed. The methodology for evaluating the risk of bias developed by the Cochrane Collaboration was used in conjunction with a methodical evaluation of pertinent literature. Excluded studies with the following characteristics: (1) incomplete and repetitive publications, (2) unable to retrieve or convert data, (3) non-English or Chinese articles.
Results:
This analysis included 13 studies covering a total of 3478 subjects. The frequency of Wilms’ Tumor 1 (WT1) mutations is 6.7%–35.73%, and the frequency of DNMT3A mutations is 12.06%–51.1%. The remission rate of patients with WT1 mutations was less than that of patients without WT1 mutations (OR = 0.22; 95% confidence interval [CI]: 0.14, 0.36; p < 0.00001; I2 = 55%). The DNMT3A mutation has no statistical significance for the prognosis of AML (OR = 1.21; 95% CI: 0.93, 1.58; p = 0.16; I2 = 80%). After removing one study, the heterogeneity of the indicator (mitigation rate) among other studies of DNMT3A mutation was dramatically reduced (OR = 0.63; 95% CI: 0.43, 0.93; p = 0.02; I2 = 0%).
Conclusions:
Our meta-analysis shows that WT1 mutations hurt the remission rate of AML. Moreover, the impact of DNMT3A mutations on AML needs to be treated with caution. Gene diagnosis is critical for the prognosis and clinical management of AML.
Get full access to this article
View all access options for this article.
References
1.
PelcovitsA, NiroulaR. Acute myeloid leukemia: A review. R I Med J (2013), 2020; 103(3):38–40.
MrózekK, MarcucciG, NicoletD, et al.Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol, 2012; 30(36):4515–4523; doi: 10.1200/JCO.2012.43.4738
4.
PachanoT, HaroE, Rada-IglesiasA. Enhancer-gene specificity in development and disease. Development, 2022; 149(11):dev186536; doi: 10.1242/dev.186536
5.
StrianoP, MinassianBA. From genetic testing to precision medicine in epilepsy. Neurotherapeutics, 2020; 17(2):609–615; doi: 10.1007/s13311-020-00835-4
6.
LindstedtI, LindgrenMA, AnderssonE, et al.The WT1 gene–its role in tumourigenesis and prospects for immunotherapeutic advances. In Vivo, 2014; 28(5):675–681.
7.
ToyotaM, SuzukiH, NishizakaT, et al.Molecular mechanisms involved in epigenetic alterations in cancer. Gan To Kagaku Ryoho, 2010; 37(9):1650–1653.
8.
LeyTJ, DingL, WalterMJ, et al.DNMT3A mutations in acute myeloid leukemia. N Engl J Med, 2010; 363(25):2424–2433; doi: 10.1056/NEJMoa1005143
9.
WongHY, SungAD, LindbladKE, et al.Molecular measurable residual disease testing of blood during AML cytotoxic therapy for early prediction of clinical response. Front Oncol, 2018; 8:669; doi: 10.3389/fonc.2018.00669
10.
TienFM, HouHA, TangJL, et al.Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA. Haematologica, 2018; 103(11):e510–e513; doi: 10.3324/haematol.2018.189043
11.
NiktorehN, WalterC, ZimmermannM, et al.Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. J Oncol, 2019; 2019:1609128; doi: 10.1155/2019/1609128
12.
XuJ, ZhangY, HuJ, et al.Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: An analysis based on TCGA database. Hematology, 2020; 25(1):79–84; doi: 10.1080/16078454.2020.1720102
13.
SuL, TanY, LinH, et al.Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance. Oncotarget, 2018; 9(38):24970–24979; doi: 10.1863/2/oncotarget.23873
14.
WangY, WengWJ, ZhouDH, et al.Wilms tumor 1 mutations are independent poor prognostic factors in pediatric acute myeloid leukemia. Front Oncol, 2021; 11:632094; doi: 10.3389/fonc.2021.632094
15.
SalehzadehS, GuerriniF, PizzanoU, et al.The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. Cancer Cell Int, 2019; 19:83; doi: 10.1186/s12935-019-0807-0
16.
SasakiK, Kanagal-ShamannaR, Montalban-BravoG, et al.Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer, 2020; 126(4):765–774; doi: 10.1002/cncr.32566
17.
AsfourIA, HegabHM, El-SalakawyWA, et al.Prognostic significance of DNMT3A gene expression and reactive nitrogen species in newly diagnosed Egyptian de novo adult acute myeloid leukemia patients. Egypt J Med Hum Genet, 2020; 21(1):1–16.
18.
OñateG, BatallerA, GarridoA, et al.Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv, 2022; 6(3):882–890; doi: 10.1182/bloodadvances.2020004136
19.
El GammalMM, EbidGT, MadneyYM, et al.Clinical effect of combined mutations in DNMT3A, FLT3-ITD, and NPM1 among Egyptian acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk, 2019; 19(6):e281–e290; doi: 10.1016/j.clml.2019.02.001
20.
ArdestaniMT, KazemiA, ChahardouliB, et al.FLT3-ITD compared with DNMT3A R882 mutation is a more powerful independent inferior prognostic factor in adult acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation: A retrospective cohort study. Turk J Haematol, 2018; 35(3):158–167; doi: 10.4274/tjh.2018.0017
21.
KumarD, MehtaA, PanigrahiMK, et al.DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in coexistent with NPM1 and FLT3 mutations. Hematol Oncol Stem Cell Ther, 2018; 11(2):82–89; doi: 10.1016/j.hemonc.2017.09.004
22.
Zechi-CeideRM, Jesus OliveiraNA, Guion-AlmeidaML, et al.Clinical evaluation and COL2A1 gene analysis in 21 Brazilian families with stickler syndrome: Identification of novel mutations, further genotype/phenotype correlation, and its implications for the diagnosis. Eur J Med Genet, 2008; 51(3):183–196; doi: 10.1016/j.ejmg.2007.12.008
23.
ToskaE, RobertsSG. Mechanisms of transcriptional regulation by WT1 (Wilms’ tumour 1). Biochem J, 2014; 461(1):15–32; doi: 10.1042/BJ20131587
24.
HuffV. Wilms’ tumours: About tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer, 2011; 11(2):111–121; doi: 10.1038/nrc3002
25.
OwenC, FitzgibbonJ, PaschkaP. Te clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol Oncol, 2009; 28(1):13–19.
26.
TrkaJ, KalinováM, HrusákO, et al.For Czech Paediatric Haematology Working Group. Real-time quantitative PCR detection of WT1 gene expression in children with AML: Prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia, 2002; 16(7):1381–1389; doi: 10.1038/sj.leu.2402512
27.
OgawaH, TamakiH, IkegameK, et al.The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood, 2003; 101(5):1698–1704; doi: 10.1182/blood-2002-06-1831
28.
PaschkaP, MarcucciG, RuppertAS, et al.Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol, 2008; 26(28):4595–4602.
29.
VirappaneP, GaleR, HillsR, et al.Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom medical research council adult leukaemia working party. J Clin Oncol, 2008; 26(33):5429–5435.
30.
HouHA, HuangTC, LinLI, et al.WT1 mutation in 470 adult patients with acute myeloid leukemia: Stability during disease evolution and implication of its incorporation into a survival scoring system. Blood, The Journal of the American Society of Hematology, 2010; 115(25):5222–5231.
31.
KrauthMT, AlpermannT, BacherU, et al.WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. Leukemia, 2015; 29(3):660–667.
32.
HollinkIHIM, van den Heuvel-EibrinkMM, ZimmermannM, et al.Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood, The Journal of the American Society of Hematology, 2009; 113(23):5951–5960.
33.
HoPA, ZengR, AlonzoTA, et al.Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): A report from the children’s oncology group. Blood, 2010; 116(5):702–710.
34.
SanoH, ShimadaA, TabuchiK, et al.WT1 mutation in pediatric patients with acute myeloid leukemia: A report from the Japanese childhood AML cooperative study group. Int J Hematol, 2013; 98(4):437–445; doi: 10.1007/s12185-013-1409-6
35.
WoodsBA, LevineRL. The role of mutations in epigenetic regulators in myeloid malignancies. Immunol Rev, 2015; 263(1):22–35; doi: 10.1111/imr.12246
36.
Russler-GermainDA, SpencerDH, YoungMA, et al.The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell, 2014; 25(4):442–454; doi: 10.1016/j.ccr.2014.02.010
37.
TangS, ShenH, MaoX, et al.FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation. Int J Hematol, 2017; 106(4):552–561; doi: 10.1007/s12185-017-2256-7
38.
MetzelerKH, HeroldT, Rothenberg-ThurleyM, et al.DNMT3A mutations associate with shorter survival and modulate the prognostic impact of mutated NPM1: An analysis based on comprehensive mutational screening of 660 AML patients treated on German AML cooperative group (AMLCG) trials. Blood, 2015; 126(23):3815–3815.
